
For young men with ED and focal pelvic/penile arterial occlusion and without documented generalized vascular disease or veno-occlusive dysfunction, penile arterial reconstruction may be considered. For men with ED, penile venous surgery is not recommended. For men with ED, low-intensity extracorporeal shock wave therapy (ESWT) should be considered investigational. For men with ED, intracavernosal stem cell therapy should be considered investigational: (Conditional Recommendation; Evidence Level: Grade C) For men with ED, platelet-rich plasma (PRP) therapy should be considered experimental. This guideline's purpose is to provide direction to clinicians and to men who have ED.
The guideline focuses on how to recognize ED, how to conduct a valid diagnostic process, and how to approach treatment with the goals of restoring sexual function and enhancing the man and his partner's quality of life (QoL) while minimizing adverse events (AEs) and diagnosis- and treatment-associated burden. The strategies and approaches recommended in this document were derived from evidence-based and consensus-based processes. There is a continually expanding literature on ED; the Panel notes that this document constitutes a clinical strategy; it is intended to be interpreted with appreciation for the dynamic, evolving understanding of ED causes and treatments. The most effective approach for a particular man is best determined by that man (in consultation with his partner, when applicable) in collaboration with the clinician and with full consideration of the relevant history, values, and goals for treatment using a shared decision-making (SDM) approach.
| Tip | Description | Expected Benefit |
|---|---|---|
| Maintain a healthy weight | Reduce obesity-related vascular risks | Improves overall circulation |
| Manage stress | Use meditation, yoga, or relaxation techniques | Reduces psychological barriers |
| Regular exercise | Boosts testosterone and improves blood flow | Enhances erectile function |
| Sleep well | Ensures hormonal balance and vascular health | Improves libido and performance |
As our understanding of ED evolves and improves, the strategies presented here will be amended to remain consistent with the highest standards of clinical care. A systematic review was conducted to identify published articles relevant to the diagnosis and treatment of ED.
| Lifestyle Factor | Recommendations | Benefits |
|---|---|---|
| Smoking | Quit smoking | Improves blood flow, reduces risk of vascular disease |
| Physical Activity | Regular exercise (e.g., 30 min/day) | Enhances circulation, boosts testosterone levels |
| Diet | Mediterranean diet, low saturated fats | Reduces cardiovascular risk, improves vascular health |
| Alcohol Consumption | Limit or avoid alcohol intake | Prevents interference with erectile function |
Literature searches were performed on English-language publications using the Pubmed, Embase, and Cochrane databases from 1/1/1965 to 7/29/2017. Data from studies published after the literature search cut-off will be incorporated into the next version of this guideline. Preclinical studies (e.g., animal models), commentary, and editorials were excluded. Additional exclusion criteria included data not relevant to current practice (e.g., reports on medications not in current clinical use, outcomes for prostheses models that are no longer available), articles focused primarily on surgical technique with minimal or no patient information or outcomes reported, no outcomes reported or outcomes data not extractable, or duplicate report of data presented elsewhere. Review article references were checked to ensure inclusion of all possibly relevant studies. Multiple reports on the same patient group were carefully examined to ensure inclusion of only sex pills for women non-redundant information. The systematic review yielded a total of 999 publications relevant to preparation of the guideline. Data on study type (e.g., published systematic review/meta-analysis, randomized controlled trial [RCT], controlled clinical trial [CCT], observational study), treatment parameters (e.g., type of treatment, dosing, follow-up), patient characteristics (e.g., age, symptom duration, ED severity), outcomes (e.g., effects on erectile function, QoL), and AEs were extracted. Quality of Studies and Determination of Evidence Strength.
A systematic review was conducted to identify published articles relevant to the diagnosis and treatment of ED. Literature searches were performed on English-language publications using the Pubmed, Embase, and Cochrane databases from 1/1/1965 to 7/29/2017. Data from studies published after the literature search cut-off will be incorporated into the next version of this guideline. Preclinical studies (e.g., animal models), commentary, and editorials were excluded. Additional exclusion criteria included data not relevant to current practice (e.g., reports on medications not in current clinical use, outcomes for prostheses models that are no longer available), articles focused primarily on surgical technique with minimal or no patient information or outcomes reported, no outcomes reported or outcomes data not extractable, or duplicate report of data presented elsewhere.
Review article references were checked to ensure inclusion of all possibly relevant studies. Multiple reports on the same patient group were carefully examined to ensure inclusion of only sex pills for women non-redundant information. The systematic review yielded a total of 999 publications relevant to preparation of the guideline. Data on study type (e.g., published systematic review/meta-analysis, randomized controlled trial [RCT], controlled clinical trial [CCT], observational study), treatment parameters (e.g., type of treatment, dosing, follow-up), patient characteristics (e.g., age, symptom duration, ED severity), outcomes (e.g., effects on erectile function, QoL), and AEs were extracted. Quality of Studies and Determination of Evidence Strength. The quality of published systematic reviews was assessed using A Measurement Tool to Assess Systematic Reviews (AMSTAR).1 Individual studies that were RCTs or CCTs were assessed using the Cochrane Risk of Bias tool.2 The quality of case-control studies and comparative observational studies was rated using the Newcastle-Ottawa Quality Assessment Scale.1004 Because there is no widely-agreed upon quality assessment tool for single cohort observational studies, the quality of these studies was not assessed.
| Product | Dosage | Quantity + Bonus | Price | |
|---|---|---|---|---|
| Cialis Generic | 20mg | 10 Pills | 31.49€ 29.99€ | |
| Levitra Generic | 20mg | 60 + 6 Pills | 131.11€ 124.87€ | |
| Kamagra 100 mg | 100 mg | 20 Pills | 86.09€ 81.99€ | |
| Viagra Super Active | 100mg | 60 + 8 Pills | 116.84€ 111.28€ | |
| Kamagra Soft Tabs | 100 mg | 60 + 4 Pills | 180.59€ 171.99€ | |
| Priligy Generic Dapoxetine | 60mg | 10 Pills | 47.63€ 45.36€ | |
| Viagra Generic | 100mg | 30 + 4 Pills | 60.91€ 58.01€ | |
| Viagra Professional | 100mg | 10 Pills | 44.09€ 41.99€ | |
| Kamagra Polo | 100mg | 32 Pills | 125.88€ 119.89€ | |
| Levitra Generic | 40mg | 60 + 4 Pills | 162.37€ 154.64€ | |
| Levitra Generic | 20mg | 30 + 4 Pills | 70.59€ 67.23€ | |
| Cialis Generic | 20mg | 180 + 10 Pills | 254.09€ 241.99€ | |
| Kamagra 100 mg | 100 mg | 120 + 6 Pills | 330.74€ 314.99€ | |
| Cialis Black | 80mg | 60 + 4 Pills | 150.98€ 143.79€ |
The categorization of evidence strength is conceptually distinct from the quality of individual studies. Evidence strength refers to the body of evidence available for a particular question and includes not only individual study quality but consideration of study design; consistency of findings across studies; adequacy of sample sizes; and generalizability of samples, settings, and treatments for the purposes of the guideline. The American Urological Association (AUA) categorizes body of evidence strength as Grade A (well-conducted and highly-generalizable RCTs or exceptionally strong observational studies with consistent findings), Grade B (RCTs with some weaknesses of procedure or generalizability or moderately strong observational studies with consistent findings), or Grade C (RCTs with serious deficiencies of procedure or generalizability or extremely small sample sizes or observational studies that are inconsistent, have small sample sizes, or have other problems that potentially confound interpretation of data). By definition, Grade A evidence is evidence about which the Panel has a high level of certainty, Grade B evidence is evidence about which the Panel has a moderate level of certainty, and Grade C evidence is evidence about which the Panel has a low level of certainty.3 AUA Nomenclature: Linking Statement Type to Evidence Strength. The AUA nomenclature system explicitly links statement type to body of evidence strength, level of certainty, magnitude of benefit or risk/burdens, and the Panel's judgment regarding the balance between benefits and risks/burdens (See the Table 1 button below). Strong Recommendations are directive statements that an action should (benefits outweigh risks/burdens) or should not (risks/burdens outweigh benefits) be undertaken because net benefit or net harm is substantial. Moderate Recommendations are directive statements that an action should (benefits outweigh risks/burdens) or should not (risks/burdens outweigh benefits) be undertaken because net benefit or net harm is moderate. Conditional Recommendations are non-directive statements used when the evidence indicates that there is no apparent net benefit or harm or when the balance between benefits and risks/burden is unclear. All three statement types may be supported by any body of evidence strength grade. Body of evidence strength Grade A in support of a Strong or Moderate Recommendation indicates that the statement can be applied to most men in most circumstances and that future research is unlikely to change confidence. Body of evidence strength Grade B in support of a Strong or Moderate Recommendation indicates that the statement can be applied to most men in most circumstances but that better evidence could change confidence.
Expert Opinion refers to a statement, achieved by consensus of the Panel, that is based on members' clinical training, experience, knowledge, and judgment for which there is no evidence. The Male Sexual Dysfunction Panel was created in 2013 by the American Urological Association Education and Research, Inc. The Practice Guidelines Committee of the AUA selected the Panel Co-Chairs who in turn appointed the additional panel members with specific expertise in this area. The AUA conducted a thorough peer review process. The draft guideline document was distributed to 35 peer reviewers.
The Panel reviewed and discussed all submitted comments and revised the draft as needed. Once finalized, the guideline was submitted for approval to the Practice Guidelines Committee, the Science and Quality Council, and subsequently to the AUA Board of Directors for final approval. Funding of the panel was provided by the AUA; panel members received no remuneration for their work. ED is defined as the inability to attain and/or maintain penile erection sufficient for satisfactory sexual performance.5 The Panel also endorses the Fourth International Consultation on Sexual Medicine's ED definition as the consistent or recurrent inability to attain and/or maintain penile erection sufficient for sexual satisfaction.6 Sexuality is a uniquely complex aspect of humanness. Sexual function depends on intact anatomical, physiological, and behavioral capacities but occurs in the multi-layered context of a man's beliefs and values about sexuality and maleness, his upbringing and sociocultural mores, his relationship with his partner and the quality of that partnership, and the partner's beliefs and values about sexual activity. Body of evidence strength Grade C in support of a Strong or Moderate Recommendation indicates that the statement can be applied to most men in most circumstances but that better evidence is likely to change confidence.
For young men with ED and focal pelvic/penile arterial occlusion and without documented generalized vascular disease or veno-occlusive dysfunction, penile arterial reconstruction may be considered. For men with ED, penile venous surgery is not recommended. For men with ED, low-intensity extracorporeal shock wave therapy (ESWT) should be considered investigational. For men with ED, intracavernosal stem cell therapy should be considered investigational: (Conditional Recommendation; Evidence Level: Grade C) For men with ED, platelet-rich plasma (PRP) therapy should be considered experimental. This guideline's purpose is to provide direction to clinicians and to men who have ED.
The guideline focuses on how to recognize ED, how to conduct a valid diagnostic process, and how to approach treatment with the goals of restoring sexual function and enhancing the man and his partner's quality of life (QoL) while minimizing adverse events (AEs) and diagnosis- and treatment-associated burden. The strategies and approaches recommended in this document were derived from evidence-based and consensus-based processes. There is a continually expanding literature on ED; the Panel notes that this document constitutes a clinical strategy; it is intended to be interpreted with appreciation for the dynamic, evolving understanding of ED causes and treatments. The most effective approach for a particular man is best determined by that man (in consultation with his partner, when applicable) in collaboration with the clinician and with full consideration of the relevant history, values, and goals for treatment using a shared decision-making (SDM) approach. As our understanding of ED evolves and improves, the strategies presented here will be amended to remain consistent with the highest standards of clinical care. Body of evidence strength Grade C is only rarely used in support of a Strong Recommendation. Conditional Recommendations also can be supported by any body ed gels of evidence strength.
When body of evidence strength is Grade A, the statement indicates that benefits and risks/burdens appear balanced, the best action depends on the man's circumstances, and future research is unlikely to change confidence. When body of evidence strength Grade B is used, benefits and risks/burdens appear balanced, the best action also depends on individual man's circumstances and better evidence could change confidence. When body of evidence strength Grade C is used, there is uncertainty regarding the balance between benefits and risks/burdens, alternative strategies may be equally reasonable, and better evidence is likely to change confidence. For some clinical issues there was little or no evidence from which to construct evidence-based statements. Where gaps in the evidence existed, the Panel provides guidance in the form of Clinical Principles or Expert Opinion with consensus achieved using a modified Delphi technique if differences of opinion emerged.4 A Clinical Principle is a statement about a component of clinical care that is widely agreed upon by urologists or other clinicians for which there may or may not be evidence in the medical literature. Expert Opinion refers to a statement, achieved by consensus of the Panel, that is based on members' clinical training, experience, knowledge, and judgment for which there is no evidence. The Male Sexual Dysfunction Panel was created in 2013 by the American Urological Association Education and Research, Inc.
| Treatment Type | Description | Typical Use |
|---|---|---|
| Oral Medications | PDE5 inhibitors like sildenafil, tadalafil | First-line treatment for many men |
| Vacuum Erection Devices | Mechanical pumps creating vacuum to draw blood | Non-invasive, for short-term use |
| Injections | Alprostadil or other agents injected into penis | For men unresponsive to pills |
| Psychotherapy | Treats underlying psychological issues | Complementary to physical treatments |
The Practice Guidelines Committee of the AUA selected the Panel Co-Chairs who in turn appointed the additional panel members with specific expertise in this area. The AUA conducted a thorough peer review process. The draft guideline document was distributed to 35 peer reviewers.
The Panel reviewed and discussed all submitted comments and revised the draft as needed. Once finalized, the guideline was submitted for approval to the Practice Guidelines Committee, the Science and Quality Council, and subsequently to the AUA Board of Directors for final approval. Funding of the panel was provided by the AUA; panel members received no remuneration for their work. ED is defined as the inability to attain and/or maintain penile erection sufficient for satisfactory sexual performance.5 The Panel also endorses the Fourth International Consultation on Sexual Medicine's ED definition as the consistent or recurrent inability to attain and/or maintain penile erection sufficient for sexual satisfaction.6 Sexuality is a uniquely complex aspect of humanness.
The quality of published systematic reviews was assessed using A Measurement Tool to Assess Systematic Reviews (AMSTAR).1 Individual studies that were RCTs or CCTs were assessed using the Cochrane Risk of Bias tool.2 The quality of case-control studies and comparative observational studies was rated using the Newcastle-Ottawa Quality Assessment Scale.1004 Because there is no widely-agreed upon quality assessment tool for single cohort observational studies, the quality of these studies was not assessed. The categorization of evidence strength is conceptually distinct from the quality of individual studies. Evidence strength refers to the body of evidence available for a particular question and includes not only individual study quality but consideration of study design; consistency of findings across studies; adequacy of sample sizes; and generalizability of samples, settings, and treatments for the purposes of the guideline. The American Urological Association (AUA) categorizes body of evidence strength as Grade A (well-conducted and highly-generalizable RCTs or exceptionally strong observational studies with consistent findings), Grade B (RCTs with some weaknesses of procedure or generalizability or moderately strong observational studies with consistent findings), or Grade C (RCTs with serious deficiencies of procedure or generalizability or extremely small sample sizes or observational studies that are inconsistent, have small sample sizes, or have other problems that potentially confound interpretation of data). By definition, Grade A evidence is evidence about which the Panel has a high level of certainty, Grade B evidence is evidence about which the Panel has a moderate level of certainty, and Grade C evidence is evidence about which the Panel has a low level of certainty.3 AUA Nomenclature: Linking Statement Type to Evidence Strength.
The AUA nomenclature system explicitly links statement type to body of evidence strength, level of certainty, magnitude of benefit or risk/burdens, and the Panel's judgment regarding the balance between benefits and risks/burdens (See the Table 1 button below). Strong Recommendations are directive statements that an action should (benefits outweigh risks/burdens) or should not (risks/burdens outweigh benefits) be undertaken because net benefit or net harm is substantial. Moderate Recommendations are directive statements that an action should (benefits outweigh risks/burdens) or should not (risks/burdens outweigh benefits) be undertaken because net benefit or net harm is moderate. Conditional Recommendations are non-directive statements used when the evidence indicates that there is no apparent net benefit or harm or when the balance between benefits and risks/burden is unclear. All three statement types may be supported by any body of evidence strength grade. Sexual function depends on intact anatomical, physiological, and behavioral capacities but occurs in the multi-layered context of a man's beliefs and values about sexuality and maleness, his upbringing and sociocultural mores, his relationship with his partner and the quality of that partnership, and the partner's beliefs and values about sexual activity.
Body of evidence strength Grade A in support of a Strong or Moderate Recommendation indicates that the statement can be applied to most men in most circumstances and that future research is unlikely to change confidence. Body of evidence strength Grade B in support of a Strong or Moderate Recommendation indicates that the statement can be applied to most men in most circumstances but that better evidence could change confidence. Body of evidence strength Grade C in support of a Strong or Moderate Recommendation indicates that the statement can be applied to most men in most circumstances but that better evidence is likely to change confidence. Body of evidence strength Grade C is only rarely used in support of a Strong Recommendation. Conditional Recommendations also can be supported by any body ed gels of evidence strength.
When body of evidence strength is Grade A, the statement indicates that benefits and risks/burdens appear balanced, the best action depends on the man's circumstances, and future research is unlikely to change confidence. When body of evidence strength Grade B is used, benefits and risks/burdens appear balanced, the best action also depends on individual man's circumstances and better evidence could change confidence. When body of evidence strength Grade C is used, there is uncertainty regarding the balance between benefits and risks/burdens, alternative strategies may be equally reasonable, and better evidence is likely to change confidence. For some clinical issues there was little or no evidence from which to construct evidence-based statements. Where gaps in the evidence existed, the Panel provides guidance in the form of Clinical Principles or Expert Opinion with consensus achieved using a modified Delphi technique if differences of opinion emerged.4 A Clinical Principle is a statement about a component of clinical care that is widely agreed upon by urologists or other clinicians for which there may or may not be evidence in the medical literature.